A clear FAQ guide on how MedTech startups can secure Medicare reimbursement for clinical trials—and when it’s worth it.
New tech payments like NTAP can’t justify long-term pricing. Here’s what MedTech founders need to know.
Why do better technologies struggle for reimbursement while outdated ones thrive? Discover the hidden bias in payer decision-making—and why second movers in MedTech face steeper evidence hurdles than the first.
FDA clearance is a milestone—not the finish line. Why reimbursement hurdles follow right after.